natgillin/translations-raw huggingface dataset:
end pinions connected to the cross axles; wherein the tractive mechanism is vertically movable and connected to the end pinions by the lateral chain, so that 
- prijenosni mehanizam (8) je okomito pokretan i povezan s krajnjim lančanicima (3) bočnim lancem (2), tako da:
An infrared window assembly mounted in an aperture provided in a housing containing an apparatus to be subjected to infrared inspection the assembly comprising: 
Infracrveni prozorski sklop 10, ugrađen u otvor načinjen u kućištu za uređaj podvrgnut infracrvenom ispitivanju, gdje sklop 10 sadrži:
at least 65% of the cells in the population express on their surfaces detectable levels of CD304 (Neuropilin 1), 
(ii) najmanje 65 % stanica u populaciji na svojoj površini izražava uočljive razine CD304 (neuropilin 1),
The sealcoat, and subsequently the enteric coat, are applied by spraying of an aqueous suspension of the coat ingredients in a Manesty 10 coater using parameters for the coating process as recommended by the manufacturers of the coating polymers (again, any suitable coater could be used). 
Brtvena ovojnica, i nakon toga enterička ovojnica, se nanesu sprejanjem vodene suspenzije sastojaka ovojnice u Manesty 10 oblagaču upotrebom parametara za postupak oblaganja prema preporuci proizvođača polimera za oblaganje (ponovno, može se upotrijebiti bilo koji prikladni oblagač).
Use of E 62, wherein the monoclonal antibody or monoclonal antibody fragment is pegylated. 
Uporaba u skladu sa zahtjevom 62, naznačena time, da monoklonsko antitijelo ili fragment monoklonskog antitijela je pegiliran.
A particularly suitable base is cesium fluoride. 
Posebno prikladna baza je cezij-klorid.
The recombinant factor VIII fusion protein of any one of claims 1 to 3, wherein the XTEN comprises an amino acid sequence at least 90% or 100% identical to an amino acid sequence as set forth in SEQ ID NOs: 50, 51, 52, 67, or 78. 
Rekombinantni fuzijski protein faktora VIII prema patentnom zahtjevu 4, naznačen time što najmanje jedan XTEN sadrži sekvencu aminokiseline koja je najmanje 90% identična sa sekvencom aminokiseline odabranom iz skupine koja sadrži SEQ ID NOs: 49, 50, 51, 52, 57, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 78 i 79-81.
The method of claim 16 wherein the breast cancer subtype is Basal or Luminal. 
Spoj za uporabu prema patentnom zahtjevu 16, naznačen time, da je podvrsta raka dojke bazalna ili luminalna.
A device as claimed in any one of the claims 11-13, wherein the heating zone comprises a single pipe or tube surrounded by a heat transfer medium not being in direct contact with the slurry of expandable microspheres. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 11-13, naznačen time što zona grijanja sadrži jednu cijev ili crijevo okruženo medijem za prijenos topline koji nije u izravnom kontaktu s muljem od rastezljivih mikrosfera.
or wherein R4 is an alkylaryl optionally substituted by one or more substituents independently selected from halogen, aryloxy, aryl, alkylamino, dialkylamino, C1-6 alkyl, carboxylic acid, carboxylic ester, carboxylic amide, sulfonamide, nitrile, or C1-6alkoxy. 
R, je alkilaril proizvoljno supstituiran s jednim ili više supstituenata koji se neovisno biraju iz niza koji sadrži halogen, ariloksi, aril, alkilamino, dialkilamino, C;4 alkil, karboksilnu kiselinu, karboksilni ester, karboksilni amid, sulfonamid, nitril, ili C,.galkoksi.
Method according to clause 1, wherein forming the final hole comprises removing plant tissue from the stem of the plant, preferably during the formation of an initial hole and additionally or alternatively during extending the size of the initial hole. 
Postupak prema zahtjevu 1, naznačen time da formiranje završnog otvora sadrži uklanjanje biljnog tkiva iz stabljike (S) biljke (P), poželjno tijekom oblikovanja početnog otvora (IH) i dodatno ili alternativno tijekom proširivanja veličine početnog otvora (IH).
autoimmune gastritis, wherein said antigen or ligand is a gastric antigen; 
autoimuni gastritis, pri čemu spomenuti antigen ili ligand je gastritični antigen;
In the preparation of pharmaceutical formulations containing a compound of the invention in the form of dosage units for oral administration the compound selected may be mixed with solid, powdered ingredients, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. 
U pripremi farmaceutskih formulacija koji sadrže spoj iz ovoga izuma u obliku doznih jedinica za oralnu uporabu, odabrani spoj može biti pomiješan s krutim, praškastim sastojcima poput laktoze, saharoze, sorbitola, manitola, škroba, amilopektina, derivata celuloze, želatine ili drugih odgovarajućih sastojaka, kao 1 s agensima za raspadanje i agensima za podmazivanje poput magnezij stearata, kalcij stearata, natrij stearil fumarata i polietilen-glikolskih voskova.
Granules, e.g. coated granules, impregnated granules and homogeneous granules, can be prepared by binding the active ingredients to solid carriers. 
Granulc, na primjer obložene granule, impregniranc granule i homogcne granulc, mogu biti pripremljene vezivanjem aktivnih sastojaka za čvrste nosače.
A compound according to claim 1, wherein ring Q is a group wherein R10 is halogen or trifluoromethyl, and X is CH or N; R2 is NH2 or CH3, and/or a pharmaceutically-acceptable salt, prodrug, solvate, isomer, or hydrate thereof. 
R40 mk gdje je Ryo halogen ili trifluorometil, a X je CH ili N; R, je NH, ili CH3, i/ili farmaceutski prihvatljiva sol, solvat, 20 stereoizomer ili hidrat ovog spoja. 3.
The compound of claim 2 wherein the cancer is a solid tumor, a sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an hematopoietic malignancy, malignant ascites, Kaposi's sarcoma, Hodgkin's disease, lymphoma, myeloma, or leukemia. 
Spoj prema patentnom zahtjevu 39, naznačen time što je rak solidni tumor, sarkom, fibrosarkom, osteom, melanom, retinoblastom, rabdomiosarkom, glioblastom, neuroblastom, teratokarcinom, hematopoetski malignitet, maligni ascites, Kaposijev sarkom, Hodgkinova bolest, limfom, mijelom ili leukemija.
The composition of any one of claims 1-5, wherein the oligosaccharide chain comprises at least one branch having the structure NeuNAc2a3GalB4GlcNAcB2Mana6. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da oligosaharidni lanac sadržava najmanje jednu granu koja ima strukturu NeuNAc20a3Galp4GlcNAcB2Mana6.
A system according to claim 1, wherein recharging of the short-range phone interface units and of the cellular hub device is chosen from any one of the group consisting of: individually; and. 
Sustav sukladno zahtjevu 1, naznačen time, da je ponovno napajanje jedinica sučelja telefona kratkog dometa i mobilnog hub uređaja odabrano s bilo kojeg iz skupine koju čine: a. - individualno; 1. b.
a longitudinally extending key blade, which is insertable into said key slot of the key plug of an associated lock, 
- < uzdužno prošireni krak ključa (102), koji se može umetnuti u navedeni utor za ključ uloška za ključ pripadajuće brave,
The use according to claim 1 or 2, wherein said vector further comprises one or more DNA sequences coding for regulatory elements selected from 5'UTRs, introns, 3'UTRs, mRNA 3' end processing sequences, polyadenylation sites, and internal ribosome entry sequences (IRES). 
Upotreba prema zahtjevu 1 ili 2, naznačena time da navedeni vektor nadalje sadrži jednu ili više DNA sekvenci kodiranja za regulatorne elemente koji se biraju iz S'UTR, introna, 3 UTR, mRNA 3' završne obrade sekvence, poliadenilacijskog mjesta, i unutarnjih ribosomskih ulaznih sekvenci (IRES).
According to another aspect, the present invention provides the use of a compound of Formula I in the manufacture of a medicament for the treatment of a kinase-mediated condition in a mammal. 
Upotreba spoja u skladu s patentnim zahtjevom 1, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje stanja posredovanog kinazama kod sisavca.
Process according to claim 1, wherein a trichlorosilane to nitro group molar ratio ranging from 1 to 5 is used. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, daje molarni omjer triklorosilana na nitro skupinu u rasponu od 1 do 5.
An antitumor agent for use in treating solid cancers, wherein a combination drug containing trifluridine and tipiracil hydrochloride in a molar ratio of 1:0.5 is administered, using a reduced amount of trifluridine, at a dose in the range of 35 to 70 mg/m2/day, and irinotecan hydrochloride hydrate is administered at a dose in the range of 45 to 144 mg/m2/day. 
HR P20182145 T1 PATENTNI ZAHTJEVI Antitumorni agens za primjenu u liječenju solidnih tumora, gdje kombinirani lijek koji sadrži trifluridin i tipiracil hidroklorid u molarnom odnosu od 1:0.5 je administriran, primjenjujući smanjenu količinu trifluridina, u dozi u opsegu od 35 do 70 mg/m"/dan, i irinotekan hidroklorid hidrat je administriran u dozi u opsegu od 45 do 144 mg/m'/dan.
An inhaler according to any one of claims 7 to 10 and 12 wherein Compound (I) and Compound (II) are in admixture with each other. 
Farmaceutska formulacija namijenjena upotrebi u liječenju bolesti dišnog sustava u skladu s patentnim zahtjevom 13, naznačena time što su Spoj (1) i Spoj (II) u smjesi jedan s drugim.
A process according to claim 11 wherein the transformation of 1,1-cyclohexanediacetic acid into the corresponding anhydride is carried out by reaction with acetic anhydride in the presence of an organic solvent. 
Postupak prema zahtjevu 11 gdje se pretvorba 1,1-cikloheksandioctene kiseline u odgovarajući anhidrid provodi reakcijom s octenim anhidridom u prisutnosti organskog otapala.
A method of promoting wound healing in a subject comprising systemically administering an effective amount of laminin-1 to the subject. 
Neka terapeutski djelotvorna količina laminina-1 za pospješivanje zacjeljivanja rane kod neke osobe, naznačena time da se taj laminin-1 primjenjuje sistemski.
A pharmaceutical composition according to any one of claims 1 to 13, wherein said composition is suitable for parenteral administration to a patient, suitable for administration to a patient by injection, or suitable for administration to a patient by infusion. 
Farmaceutski sastav prema bilo kojem zahtjevu od 11 do 26, naznačen time, da je spomenuti sastav pogodan za parenteralnu primjenu na pacijentu. Farmaceutski sastav prema bilo kojem zahtjevu od 11 do 26, naznačen time, da je spomenuti sastav pogodan za primjenu na pacijentu pomoću injekcije.
A succinate salt of formula II or a hydrate thereof: 
Sukcinat formule II ili hidrat te soli: Gi) mazut
culturing said host cells and allowing for expression of VH and/or VL polypeptides, obtaining said binding molecules. A method according to claim 1, further comprising taking a sample of said cultured cells, the sample comprising at least one of said binding molecules, and subjecting the samples to at least one functional assay, and selecting at least one cell that expresses a binding molecule with desired characteristics. 
Postupak sukladno patentnom zahtjevu 1 ili 2, koji dalje sadrži uzimanje uzorka od navedenih kultiviranih stanica, pri čemu uzorak sadrži najmanje jedno od navedenih antitijela, i podvrgavanje uzorka barem jednom funkcionalnom testu, i odabir najmanje jedne stanice koja eksprimira protitijelo s željenom specifičnosti vezivanja, afinitetom, neutralizujućim djelovanjem, aktivnošću ubijanja tumorskih stanica i/ili inhibicijskom aktivnošću proliferacije.
Ice was added, the reaction mixture was poured into a saturated aqueous solution of ammonium chloride and the mixture was extracted with ethyl acetate. 
Doda se led, reakcijsku smjesu se izlije u zasićenu vodenu otopinu amonijevog klorida, a smjesu ekstrahira etil-acetatom.
In one embodiment, the compound of Formula I is a compound of Formula Ia, having predominantly the (S) configuration at the carbon attached to Y2: 
Spoj prema zahtjevu 2, naznačen time da spoj prema Formuli I je spoj sa Formulom Ia. koji ima pretežno (S) konfiguraciju na ugljiku vezanom na Y*:
a single nucleic acid molecule comprising the adenovirus E1 A coding sequence, the adenovirus E1B-19K coding sequence, and the adenovirus E1B-55K coding sequence, wherein the E1 A coding sequence and at least one of the E1B-19K and E1B-55K coding sequences are separated by at least 8 kb; and ii) two or more nucleic acid molecules together comprising the adenovirus E1 A, the adenovirus E1B-19K coding sequence and the adenovirus E1B-55K coding sequence, wherein the E1 A coding sequence and at least one of the E1B-19K and E1B-55K coding sequences are separated by at least 8 kb when the two or more nucleic acid molecules would form a single molecule by end-to-end joining before integrating into the precursor cell's genome; 
Postupak pripreme stanice koja ima adenovirus EIA i E1B-I9K i E1B-55K kodirajuće sekvence integrirane u njezin genom, naznačen time da postupak sadrži korake uvođenja u prekursorsku stanicu: jednostruke molekule nukleinske kiseline koja sadrži ELA 1 E1B-19K i El B-55K kodirajuće sekvence, pri čemu navedena E1A 1 barem jedna od E1B kodirajućih sekvenci su odvojene sa barem 8 kb; ili dvije ili više molekula nukleinske kiseline sadrži ELA 1 E1B-19K 1 E1B-55K kodirajuće sekvence pri čemu navedena E1A 1 barem jedna od E1B kodirajućih sekvenci su odvojene sa barem 8 kb kada bi navedene dvije ili više molekula nukleinske kiseline mogle tvoriti jednostruku molekulu spajanjem kraja sa krajem.
Compound (I) according to claim 1 for use according to claim 1 and a further compound selected from the group consisting of sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant for use in the treatment of psychosis, in particular schizophrenia or other diseases involving psychotic symptoms, such as, e.g., Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder as well other psychotic disorders or diseases that present with psychotic symptoms, e.g. bipolar disorder, such as mania in bipolar disorder, and for treatment of psychosis in Parkinson's Disease, wherein Compound (I) is administered semiweekly or weekly in an instant release formulation (IR-formulation), an extended, controlled or a delayed release formulation for oral administration in a dose corresponding to between 20 mg/week and 50 mg/week calculated as the free base of Compound (I). 
(D prema zahtjevu 1 za uporabu prema zahtjevu 1 i daljnji spoj izabran iz skupine koja se sastoji od sertindola, olanzapina, risperidona, kvetiapina, aripiprazola, haloperidola, klozapina, ziprasidona i osanetanta za uporabu u liječenju psihoze, posebno shizofrenije ili drugih bolesti koje uključuju psihotične simptome, poput npr. shizofreniformnog poremećaja, shizoafektivnog poremećaja, deluzijskog poremećaja, kratkog psihotičnog poremećaja, dijeljenog psihotičnog poremećaja kao i drugih psihotičnih poremećaja ili bolesti koje se očituju psihotičnim simptomima, npr. bipolarni poremećaj, poput manije u bipolarnom poremećaju, te za liječenje psihoze u Parkinsonovoj bolesti, pri čemu se Spoj (I) primjenjuje dvaput tjedno ili jednom tjedno u formulaciji sa trenutnim ispuštanjem (IR-formulacija), u formulaciji sa produženim, kontroliranim ili odgođenim ispuštanjem, za oralnu primjenu u dozi koja odgovara između 20 mg/tjedan 1 50 mg/tjedan računato kao slobodna baza Spoja (1).
a cumulative total amount of tryptophan per unit volume greater than 1.0 mM; 
(vii) kumulativna ukupna količina triptofana po jedinici volumena veća od približno 1,0 mM;
The method of E 25, wherein the IL-23 antagonist binds to and inhibits the activity of IL-23p19. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 25, naznačen time, da se IL-23 antagonist veže na i inhibira djelovanje IL-23p19.
The reaction was stirred for 1h at 0°C and then at room temperature for 1h. 
Reakcija se miješa tijekom 1 h na O*C i tada na sobnoj temperaturi tijekom 1 h.
Said hemangioblasts may be plated on a matrix. Said matrix may comprise one or more of: transforming growth factor beta (TGF-beta), epidermal growth factor (EGF), insulin-like growth factor 1, bovine fibroblast growth factor (bFGF), and/or platelet-derived growth factor (PDGF). 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što matriks sadrži jedan ili više od transformirajućeg čimbenika rasta B (TGFPB), čimbenika rasta epiderme (EGF), inzulinu sličnog čimbenika rasta 1, goveđeg čimbenika rasta fibroblasta (bFGF), i/ili čimbenika rasta iz trombocita (PDGF).
A castable refractory material according to any one of the preceding claims, including a non-wetting agent in the range 0% - 12% by weight. 
Vatrostalni materijal koji se može izlijevati u skladu s bilo kojim od prethodnih patentnih zahtjeva, koji sadrži sredstvo protiv vlaženja u opsegu od 0 težinskih % do 12 težinskih %.
The combined ether washings were filtered and evaporated to give 2-azidopropan-1-ol (12.3 g) as a pale brown oil which was shown by g.l.c. 
Spojeni eterske otopine od pranja se filtriraju i upere da bi se dobio 2-azidopropan-1-ol (12,3 #) kao svijetlo smeđe ulje za koje je pokazano g.l.c.
the first volume is pressurized, and the pressure is maintained in the first volume over a predetermined period of time while the second volume is at the initial pressure and separated from the first volume; 
prvi volumen (V1) je pod tlakom, a tlak se održava u prvom volumenu tijekom unaprijed određenog vremenskog razdoblja dok je drugi volumen na početnom tlaku i odvojen je od prvog volumena,
The binders which may be used in preparing such a fuel element are well known in the art. 
Vezivna sredstva koja se mogu koristiti za pravljenje takvog gorivog elementa su dobro poznata u znanosti.
The pharmaceutical composition for oral administration according to claim 18, wherein the additive which allows water to penetrate into the formulation accounts for 3% by weight to 80% by weight. 
Tableta za oralnu primjenu prema zahtjevu 16, gdje aditiv koji omogućuje penetraciju vode u oblik čini 3% težine do 80% težine.
The method of claim 37, wherein the solvent system of the inner layer coating preparation or the isolation layer coating preparation is aqueous. 
Postupak za koji se traži zaštita patenta u patentnom zahtjevu 11, pri čemu je sustav otapala unutarnjeg pripravka za oblaganje vodik.
In a second embodiment the phase purity is at least about 25% of the form with the above solid-state physical characteristics. 
U drugoj implementaciji fazna čistoća je najmanje oko 25% od oblika sa gore opisanim fizičkim karakteristikama krutine .
The computer cluster system according to claim 1, wherein each hardware computation node from among the plurality of hardware computation nodes comprises at least one of a group of components, said group of components comprising: a multi-core processor, a cluster, a computer, a workstation, and a multi-purpose processor. 
Način raspoređivanja računalnog klastera u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, da svaki računalni čvor (CN) sadržava najmanje jednu od skupina komponenti, pri čemu navedena skupina sadržava: višejezgreni procesor, klaster, računalo, radnu stanicu i višenamjenski procesor.
comparing the detected level of JCV antibody in the pre-incubated biological sample to the level of JCV antibody detected in a biological sample obtained from the subject that was pre-incubated in a solution without HPVLPs, and was contacted with HPVLP immobilized on a solid substrate under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, wherein a decrease above a specified percentage in the detected level of JCV antibody in the pre-incubated biological sample compared to the biological sample obtained from the subject that was pre-incubated in a solution without HPVLPs indicates that the sample is positive for JCV antibody, and a change in the detected level of JCV antibody below a specified percentage indicates that there is no JCV-specific antibody present in the sample, 
uspoređivanju detektirane razine protutijela protiv JCV u predinkubiranom biološkom uzorku s razinom protutijela protiv JCV detektiranom u biološkom uzorku dobivenom iz subjekta predinkubiranom u otopini bez HPVLP-a, te stavljenom u kontakt s HPVLP imobiliziranim na čvrsti supstrat u uvjetima pogodnim za vezanje protutijela protiv JCV u uzorku na HPVLP, gdje se HPVLP-i sastoje od više od 5, najmanje 50, 150 ili 360 polipeptida VP1.
Total Tablet Weight 
/Ukupna masa tablete
The scaffold mimetic of a fusion peptide according to claim 12 or 13, wherein component (III) comprises at least 4, preferably at least 10, more preferably at least 20 amino acid residues of the N-terminal sequence of GLP-2 as in proglucagon or of GLP-1 (7-37). 
Fuzijski peptid prema patentnom zahtjevu 9 ili 10, naznačen time da komponenta (III) obuhvaća najmanje 4, poželjno najmanje 10, a još poželjnije najmanje 20 aminokiselinskih ostataka N-terminalne sekvence od GLP-2 kao u proglukagonu ili od GLP-1(7-37). t>&
The transmission apparatus according to claim 8, wherein the first aggregation level value is 1 or 2 and the second aggregation level value is 4 or 8. 
Naprava za prijem sukaldno jednom od zahtjeva od 5 do 7, naznačena time da je prva vrijednost razine agregacije 2 i da je druga vrijednost razine agregacije 4 ili 8.
The mixture was transferred to a fluidization rotogranulator (Glatt GPCG1), and 1500 ml of ion-exchanged water were sprayed onto it. 
Smjesa je prenesena u fluidizačijski rotacijski granulator (Glatt GPCG1), pa je na nju raspršeno 1500 ml ionsko-izmjenjivačke vode.
For example, the antioxidant can be selected from among lipoic acid, thioglycerol (also known as monothioglycerol) and analogs thereof, propyl gallate, methionine, cysteine, metabisulfites, sodium formaldehyde sulfoxylate, phenol-containing aromatic and aliphatic compounds, dihydrolipoic acid and mixtures of the foregoing. 
Stabilan pri dugotrajnom skladištenju, nevodeni tekući pripravak s bendamustinom prema bilo kojem od prethodnih zahtjeva, naznačen time, da je antioksidans odabran 1z skupine koju čine tioglicerol, monotioglicerol, lipoinska kiselina, propil galat, metionin, cistein, metabisulfiti, natrijev formaldehid sulfoksilat, aromatski i alifatski spojevi s fenolom i dihidrolipoinska kiselina.
Production of Monoclonal Antibodies of the Invention 
Datum podnošenja europske prijave patenta:
on the interior side of outer shell (61) area provided with said thermally insulating material annular layer (73) are attached two thermally insulating ring like flat surfaces (74, 75), 
sa unutarnje strane vanjskog kućišta (61), koja je također obložena prstenastim pojasom spomenutog termoizolacijskog materijala (73), postavljene su dvije prstenaste ravne površine (74, 75);
it has an increased Fc-mediated cellular cytotoxicity which is at least 2 times higher than the Fc-mediated cellular cytotoxicity of at least one antibody molecule composition from the same antibody molecule when expressed in the cell line ATCC No. 
- ima povećanu staničnu citotoksičnost vezanu uz Fc, koja je najmanje 2 puta veća od stanične citotoksičnosti vezane uz Fc pripravka s najmanje jednom molekulom protutijela za istu molekulu protutijela kada se eksprimira u staničnoj liniji ATCC No.
Separate dosage forms or a package according to any of claims 9-11, wherein said second agent is for separate administration. 
Zasebni oblici doziranja u skladu s patentnim zahtjevima 13-15, pri čemu je navedeni drugi terapiski agens za zasebnu primjenu.
In one embodiment, one of the 3 nucleotide differences in the nucleotide sequence of the antisense strand is a nucleotide mismatch in the seed region of the antisense strand. 
Dvolančano RNA: sredstvo prema zahtjevu 1, naznačeno time da jedna od 3 nukleotidne razlike u nukleotidnoj sekvenci protusmjernog lanca je nukleotidna neusklađenost u sjemenskoj regiji protusmjernog lanca.